Endocrinology Drugs Market To Grow By Usd 36.55 Billion From 2022 To 2027, North America To Account For 45% Of Market Growth- Technavio

(MENAFN- PR Newswire) NEW YORK, Sept. 11, 2023 /PRNewswire/ -- The
endocrinology drugs market size is expected to grow by USD 36.55 billion from 2022 to 2027. In addition, the momentum of the market will be progressing at a CAGR of
during the forecast period, according to Technavio Research. The market is segmented by distribution channel
(Hospital pharmacies, Retail pharmacies, and Online pharmacies), therapy area (diabetes drugs, HGH, thyroid hormone, others), and geography (North America, Europe, Asia, and Rest of World (ROW)).
North America
is estimated to
to the growth of the global market. The North American market is expected to have a rapid growth momentum due to the aging population, increasing the risk of endocrine disorders. The high prevalence of diabetes,
the most common endocrine disorder, is the main revenue driver for the regional market. Furthermore, patient education initiatives by organizations such as the American Diabetes Association and the American Association of Diabetes Educators are also driving market growth in the region. In addition, training programs conducted by the CDC and the National Institute of Diabetes, Digestive, and Kidney Diseases for healthcare professionals are expected to drive the market growth during the forecast period.
This report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment. Read PDF Sample Report

Continue Reading
Technavio has announced its latest market research report titled Global Endocrinology Drugs Market 2023-2027
Technavio has announced its latest market research report titled Global Endocrinology Drugs Market 2023-2027

Company Profile:

Abbott Laboratories, AcePharmaceuticals Corp., Ascendis Pharma AS, Bayer AG, Beta Cell NV, Biocon Ltd., Eli Lilly and Co., Endo International Plc, F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Hanmi Pharm Co. Ltd., Ipsen Pharma, Merck & Co. Inc., Novartis AG, Novo Nordisk AS, Oramed Pharmaceuticals Inc., Pfizer Inc., Sanofi SA, Takeda Pharmaceutical Co. Ltd., and VeroScience LLC

  • AcePharmaceuticals Corp.:
    The company offers endocrinology drugs such as Natesto.

To gain access to more Company profiles available with Technavio, buy the report!

Endocrinology Drugs Market: Segmentation Analysis

The market share growth by the diabetes drugs
will be significant during the forecast period.
The most common non-communicable disease in the world is diabetes. Three major types of diabetes include type-1 diabetes, type-2 diabetes, and gestational diabetes. In particular, due to the increasing incidence of diabetes worldwide, it is expected that the diabetic drugs segment will experience an increase in growth. This indication, which was typically considered a disease with the onset of aging and in obese individuals, is now showing incidence in young and middle-aged people as well as non-obese individuals.

Learn about the contribution of each segment summarized in concise
infographics and thorough descriptions. View a PDF Sample Report

"Besides analyzing the current market scenario, our report examines historic data from 2017 to 2021"- Technavio

Endocrinology Drugs Market: Driver & Trend:

  • Increase in incidence of endocrine disorders
  • Promising pipeline for endocrinology
  • Research in novel dosage formulations and drug delivery systems

The increase in the incidence of endocrine disorders is the key factor driving the endocrinology drug market growth.
The increasing prevalence of endocrine disorders can be attributed to the increasing aging of the world population. Diabetes is the most common endocrine disorder and its prevalence is increasing across the globe, making it a major public health problem. Furthermore, the prevalence of diabetes also has a high economic impact due to the costs involved. Direct diabetes-related costs include hospital costs, costs associated with the purchase of medications and biologics, primary care, and specialist visits. Hence, the increasing prevalence of endocrine disorders and the growing elderly population at high risk of these diseases will drive the market growth during the forecast period.

Identify key trends, drivers, and challenges in the market. Download to gain access to this information.

Related Reports:

The migraine drugs market size is estimated to grow by
1,139.92 million
at a
CAGR of 6.05%
between 2022 and 2027.
This global migraine drugs market report extensively covers market segmentation
by end-user (hospitals, retail, and online), type (preventive and abortive), and geography (North America, Europe, Asia, and Rest of the World (ROW)). The increase in the number of patients suffering from migraine is driving growth in the migraine drugs market.

anti-obesity drugs market size
is estimated to grow at a
CAGR of 12.5%
between 2022 and 2027 and the size of the market is forecast to increase by
USD 13,693.43 million. This anti-obesity drugs market
report extensively covers
market segmentation by type (class III anti-obesity drugs, class II
anti-obesity drugs, and class I anti-obesity drugs), drug class (peripherally acting drugs and centrally acting drugs), and geography (North America, Europe, Asia, and Rest of World (ROW)).
The use of bariatric surgery limited for morbid obesity is driving the market growth.

What are the key data covered in this endocrinology drugs market report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the growth of the
    endocrinology drugs market between 2022 and 2027.
  • Precise estimation of the endocrinology drugs market size and its contribution to the market in foon the parent market
  • Accurate predictions about
    upcoming trends and changes in consumer behavior
  • Growth of the endocrinology drugs market across
    North America,
    Asia, and ROW
  • A thorough analysis of the market's competitive landscape and detailed information about companies
  • Comprehensive analysis of factors that will challenge the growth of endocrinology drugs market companies

Table of Contents

1 Executive Summary

2 Market Landscape

3 Market Sizing

4 Historic Market Size

5 Five Forces Analysis

6 Market Segmentation by Therapy Area

7 Market Segmentation by Distribution Channel

8 Customer Landscape

9 Geographic Landscape

10 Drivers, Challenges, and Trends

11 Company Landscape

12 Company Analysis

13 Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
[email protected]

SOURCE Technavio


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.